Anagrelide Viatris (previously Anagrelide Mylan)

About this medicine

Anagrelide Viatris is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.An at-risk patient An at-risk essential thrombocythaemia patient is defined by one or more of the following features: >60 years of age or a platelet count >1,000 x 10?/l or a history of thrombo-haemorrhagic events.

Key Information